Herein, we reported a case of lung adenocarcinoma without driver alteration that developed resistance after multiple cycles of pembrolizumab treatment and newly emerged CD74-ROS1 fusion and achieved a partial response after entrectinib treatment. Here, ROS1 is linked to lung adenocarcinoma.